Acorda Therapeutics Inc Quick Ratio (ACORQ) starting from the first quarter 2024 to first quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Acorda Therapeutics Inc   (ACORQ)

Acorda Therapeutics Inc 's Quick Ratio

ACORQ's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the first quarter 2024, Quick Ratio deteriorated to 0.04 a new company low.

Within Biotechnology & Pharmaceuticals industry 157 other companies have achieved higher Quick Ratio than Acorda Therapeutics Inc in first quarter 2024. While Quick Ratio total ranking in the first quarter 2024 has deteriorated compared to the prior quarter from 1917 to 4334.

Explain Quick Ratio?
How much Cash & cash equivalents ACORQ´s has?
What are ACORQ´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ACORQ Quick Ratio (Mar 31 2024)
Q1		 (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1
Y / Y Current Liabilities Change 570.03 % 511.88 % 6.41 % -29.91 % -27.86 %
Y / Y Cash & cash equivalent Change -69.05 % -19.12 % 56.88 % 9.27 % -5.08 %
Quick Ratio MRQ 0.04 0.13 0.73 0.88 0.91
ACORQ's Total Ranking # 4334 # 1917 # 1750 # 1918 #
Seq. Current Liabilities Change -4.25 % 419.3 % 55.16 % -13.15 % -12.56 %
Seq. Cash & cash equivalent Change -69.16 % -6.49 % 28.48 % -16.48 % -19.4 %



Quick Ratio first quarter 2024 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 158
Healthcare Sector # 954
Overall Market # 4334


Quick Ratio Statistics
High Average Low
7.6 2.21 0.04
(Sep 30 2014)   (Mar 31 2024)




Financial Statements
Acorda Therapeutics Inc 's Current Liabilities $ 222 Millions Visit ACORQ's Balance sheet
Acorda Therapeutics Inc 's Cash & cash equivalent $ 9 Millions Visit ACORQ's Balance sheet
Source of ACORQ's Sales Visit ACORQ's Sales by Geography


Cumulative Acorda Therapeutics Inc 's Quick Ratio

ACORQ's Quick Ratio for the trailling 12 Months

ACORQ Quick Ratio

 (Mar 31 2024)
12 Months		 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months
Y / Y Current Liabilities TTM Growth 242.3 % 102.84 % -21.02 % -32.2 % -34.62 %
Y / Y Cash & cash equivalent TTM Growth -12.68 % 4.52 % 3.46 % -16.85 % -29.97 %
Quick Ratio TTM 0.18 0.35 0.87 0.8 0.72
Total Ranking TTM # 3749 # 3558 # 3585 # 3696 #
Seq. Current Liabilities TTM Growth 55.81 % 134.28 % 1.9 % -7.97 % -7.67 %
Seq. Cash & cash equivalent TTM Growth -17.65 % -5.72 % 10.35 % 1.92 % -1.43 %

Quick ratio ranking by company, industry and sector >> Back to ACORQ Financial Strength Comparisons >> Go to Compare ACORQ Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q1 2024 to $222.34 millions, cumulative Quick Ratio decreased to 0.18 below the Acorda Therapeutics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 158 other companies have achieved higher Quick Ratio than Acorda Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2023 from 3558 to 3749.

Explain Quick Ratio?
How much Cash & cash equivalents ACORQ´s has?
What are ACORQ´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 159
Healthcare Sector # 1009
Within the Market # 3749


trailing twelve months Quick Ratio Statistics
High Average Low
4.96 2.12 0.29
(Sep. 30, 2014)   (Mar 31 2024)




Companies with similar Quick Ratio in the quarter ending Mar 31 2024, within Biotechnology & Pharmaceuticals Industry Quick RatioMar 31 2024 MRQ Cash & cash equivalentMar 31 2024 MRQ Current Liabilities
Brainstorm Cell Therapeutics inc   0.11 $ 0.779  Millions$ 6.831  Millions
Calidi Biotherapeutics Inc   0.08 $ 1.143  Millions$ 14.953  Millions
Alvotech  0.05 $ 51.428  Millions$ 1,035.882  Millions
Acorda Therapeutics Inc   0.04 $ 9.364  Millions$ 222.337  Millions
Mosaic Immunoengineering Inc   0.02 $ 0.065  Millions$ 4.108  Millions
Pelthos Therapeutics Inc   0.01 $ 0.040  Millions$ 2.901  Millions
Zivo Bioscience Inc   0.01 $ 0.032  Millions$ 3.085  Millions

Date modified: 2026-09-26T07:16:13+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.